Department of Gastroenterology, Internal Medicine, Kitasato University Hospital, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.
Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Clin J Gastroenterol. 2022 Dec;15(6):1108-1114. doi: 10.1007/s12328-022-01686-6. Epub 2022 Aug 24.
Hepatoid adenocarcinoma (HAC) is an adenocarcinoma with components similar to those of hepatocellular carcinoma. Primary HAC of the gallbladder is extremely rare; to our knowledge, there is no consensus on the treatment after diagnosis. We reported an 82-year-old Japanese female of primary HAC of the gallbladder with postoperative recurrence that responded to lenvatinib. A total of 9 months has passed since the start of chemotherapy with lenvatinib, and the patient is in good general condition. To establish an effective treatment for primary HAC of the gallbladder, further accumulation and investigation of cases are recommended.
肝胆管细胞癌(Hepatoid adenocarcinoma,HAC)是一种具有类似肝细胞癌成分的腺癌。胆囊原发性 HAC 极为罕见;据我们所知,目前对于确诊后的治疗尚无共识。我们报告了一例 82 岁日本女性胆囊原发性 HAC,术后复发后对仑伐替尼有反应。自开始仑伐替尼化疗以来已经过去了 9 个月,患者的一般状况良好。为了建立对胆囊原发性 HAC 的有效治疗方法,建议进一步积累和调查病例。